In Reply to Xue W, Ribalov R, Zhou Z-Y, et al. Re: Ganz ML, Chavan A, Dhanda R, et al. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. J Med Econ. 2021;24(1):103–113
Year: 2021
Type: letter
Abstract: Dear Editor,We appreciate the interest from Xue et al. in our cost-effectiveness analysis of valbenazine versus deutetrabenazine for the treatment of tardive dyskinesia (TD)1, and are gratified tha...
Source: Journal of Medical Economics
Authors: Michael Serbin, Charles Yonan, Michael L. Ganz
Institution: Neurocrine Biosciences (United States)
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: diamond
OpenAlex ID: W3174596410